AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
Cooperation with Lysando
|AiCuris and Lysando join forces in the fight against antimicrobial resistance|
Lysando AG and AiCuris today annouced the signing of a long-term cooperation for the development and optimization of Artilysin®-based drug candidates for various anti-bacterial indications.
Investment in Wuppertal
|AiCuris plans its further growth in Wuppertal and intends investing millions at the site|
Investments amounting to several million euros are planned over the next few years for the modernisation and expansion of the premises and laboratories.